192 related articles for article (PubMed ID: 36149072)
1. [Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?].
Buschiazzo H; Dorati C; Iusef Venturini N; Cañas M; Urtasun MA; Marin GH; Prozzi GR; Rivadulla PA; Trionfetti M; Mordujovich Buschiazzo P
Rev Fac Cien Med Univ Nac Cordoba; 2022 Sep; 79(3):241-247. PubMed ID: 36149072
[TBL] [Abstract][Full Text] [Related]
2. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
3. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
4. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
Craveiro NS; Lopes BS; Tomás L; Almeida SF
Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
6. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
7. Withdrawn medicines included in the essential medicines lists of 136 countries.
Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
[TBL] [Abstract][Full Text] [Related]
8. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
9. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
10. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D; Alves C; Batel Marques F
Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
[TBL] [Abstract][Full Text] [Related]
11. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
13. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
14. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN--a resource for withdrawn and discontinued drugs.
Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators Worldwide.
Lee KH; Kim GJ; Kim JH
J Korean Med Sci; 2015 Nov; 30(11):1567-76. PubMed ID: 26538999
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of drugs withdrawn from the market.
Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
[TBL] [Abstract][Full Text] [Related]
19. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009.
Lexchin J
Open Med; 2014; 8(1):e14-9. PubMed ID: 25009681
[TBL] [Abstract][Full Text] [Related]
20. Classification of nervous system withdrawn and approved drugs with ToxPrint features via machine learning strategies.
Onay A; Onay M; Abul O
Comput Methods Programs Biomed; 2017 Apr; 142():9-19. PubMed ID: 28325450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
